BACKGROUND: Early outpatient follow-up after acute myocardial infarction (AMI) is recommended in guidelines, but its relationship with the use of evidence-based therapies is unknown. METHODS: We evaluated 1516 patients hospitalized with AMI from the multicenter Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery registry. Early follow-up was defined as patient- reported visits with a primary care physician or cardiologist within 1 month after discharge. The primary outcomes were use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and statins in eligible patients at 6 months. Multivariable analyses assessed the association between early follow-up and medication use at 6 months, adjusting for patient and clinical characteristics. Secondary analyses compared medication use at 6 months for patients receiving collaborative follow-up from a single provider vs those receiving follow-up from both provider types. RESULTS: Among the cohort, 34% reported no outpatient follow-up during the month following discharge. Rates of medication prescription among appropriate candidates were similar at hospital discharge for both follow-up groups. Compared with those not receiving early follow-up, those receiving early follow-up were more likely to be prescribed beta-blockers (80.1% vs 71.3%; P = .001), aspirin (82.9% vs 77.1%; P = .01), or statins (75.9% vs 68.6%; P = .005) at 6 months. In multivariable analyses, a persistent relationship remained between early follow-up and beta-blocker use (risk ratio, 1.08; 95% confidence interval, 1.02-1.15). In secondary analyses, statin use was higher in patients receiving collaborative follow-up (risk ratio, 1.11; 95% confidence interval, 1.01-1.22). CONCLUSIONS: Early outpatient follow-up and collaborative follow-up after AMI is associated with higher rates of evidence-based medication use. Although further studies should assess whether this relationship is causal, these results support current guideline recommendations for follow-up after AMI.
BACKGROUND: Early outpatient follow-up after acute myocardial infarction (AMI) is recommended in guidelines, but its relationship with the use of evidence-based therapies is unknown. METHODS: We evaluated 1516 patients hospitalized with AMI from the multicenter Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery registry. Early follow-up was defined as patient- reported visits with a primary care physician or cardiologist within 1 month after discharge. The primary outcomes were use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and statins in eligible patients at 6 months. Multivariable analyses assessed the association between early follow-up and medication use at 6 months, adjusting for patient and clinical characteristics. Secondary analyses compared medication use at 6 months for patients receiving collaborative follow-up from a single provider vs those receiving follow-up from both provider types. RESULTS: Among the cohort, 34% reported no outpatient follow-up during the month following discharge. Rates of medication prescription among appropriate candidates were similar at hospital discharge for both follow-up groups. Compared with those not receiving early follow-up, those receiving early follow-up were more likely to be prescribed beta-blockers (80.1% vs 71.3%; P = .001), aspirin (82.9% vs 77.1%; P = .01), or statins (75.9% vs 68.6%; P = .005) at 6 months. In multivariable analyses, a persistent relationship remained between early follow-up and beta-blocker use (risk ratio, 1.08; 95% confidence interval, 1.02-1.15). In secondary analyses, statin use was higher in patients receiving collaborative follow-up (risk ratio, 1.11; 95% confidence interval, 1.01-1.22). CONCLUSIONS: Early outpatient follow-up and collaborative follow-up after AMI is associated with higher rates of evidence-based medication use. Although further studies should assess whether this relationship is causal, these results support current guideline recommendations for follow-up after AMI.
Authors: Nilay D Shah; Shannon M Dunlay; Henry H Ting; Victor M Montori; Randal J Thomas; Amy E Wagie; Véronique L Roger Journal: Am J Med Date: 2009-06-26 Impact factor: 4.965
Authors: Hoang V Tran; Darleen Lessard; Mayra S Tisminetzky; Jorge Yarzebski; Edgard A Granillo; Joel M Gore; Robert Goldberg Journal: Am J Cardiol Date: 2017-11-22 Impact factor: 2.778
Authors: Rebecca Vigen; John A Spertus; Thomas M Maddox; P Michael Ho; Philip G Jones; Suzanne V Arnold; Frederick A Masoudi; Steven M Bradley Journal: Circ Cardiovasc Qual Outcomes Date: 2014-11-11
Authors: Ellen Funkhouser; Thomas K Houston; Deborah A Levine; Joshua Richman; Jeroan J Allison; Catarina I Kiefe Journal: Circ Cardiovasc Qual Outcomes Date: 2010-12-07
Authors: Rishi K Wadhera; Deepak L Bhatt; Amy J H Kind; Yang Song; Kim A Williams; Thomas M Maddox; Robert W Yeh; Liyan Dong; Gheorghe Doros; Alexander Turchin; Karen E Joynt Maddox Journal: Circ Cardiovasc Qual Outcomes Date: 2020-03-31
Authors: Javier Muñiz; Juan J Gómez-Doblas; María I Santiago-Pérez; Iñaki Lekuona-Goya; Nekane Murga-Eizagaetxebarría; Eduardo de Teresa-Galván SS; José M Cruz-Fernández; Alfonso Castro-Beiras Journal: Health Qual Life Outcomes Date: 2010-11-22 Impact factor: 3.186
Authors: Steven M Bradley; Chris L Bryson; Charles Maynard; Thomas M Maddox; Stephan D Fihn Journal: BMC Cardiovasc Disord Date: 2011-07-09 Impact factor: 2.298
Authors: Elizabeth G Sides; Louise O Zimmer; Leslie Wilson; Wenqin Pan; Daiwai M Olson; Eric D Peterson; Cheryl Bushnell Journal: BMC Public Health Date: 2012-07-25 Impact factor: 3.295